Immunome Doses First Patient in Phase 1 Trial of FAP-Targeted Radioligand Therapy IM-3050
IMNM has more than doubled off its 52-week low of $8.665.
Summary
Immunome has dosed the first patient in a Phase 1 trial of IM-3050, a lutetium-177 radioligand therapy targeting FAP, which is expressed in 75% of solid tumors. This marks the first clinical data point for the program, moving it from preclinical to early-stage clinical evaluation. The trial will assess safety, dosing, and preliminary efficacy in advanced solid tumors. The milestone adds a new clinical asset to a pipeline that already includes an NDA-submitted varegacestat and two other clinical-stage ADCs. With $582.7M in cash as of Q1 2026, the company is funded to advance multiple programs, but the early-stage nature of IM-3050 means any efficacy signals are likely 12-18 months away.
At the time of this announcement, IMNM was trading at $21.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $8.67 to $27.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.